Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T cells during chronic human immunodeficiency virus type 2 infection by Gautier, D. et al.
JOURNAL OF VIROLOGY, Nov. 2007, p. 12685–12688 Vol. 81, No. 22
0022-538X/07/$08.000 doi:10.1128/JVI.01131-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Efficient Thymopoiesis Contributes to the Maintenance of Peripheral
CD4 T Cells during Chronic Human Immunodeficiency
Virus Type 2 Infection
David Gautier,1 Ste´phanie Beq,1 Catarina S. Cortesa˜o,2 Ana E. Sousa,2 and Re´mi Cheynier1*
De´partement de Virologie, Institut Pasteur, 28 rue du Dr. Roux, 75015 Paris, France,1 and Unidade de Imunologia Clı´nica,
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal2
Received 24 May 2007/Accepted 27 August 2007
Human immunodeficiency virus type 2 (HIV-2) infection leads to a lifelong asymptomatic period in the
majority of patients. Even in patients with progressive disease, a slow CD4 count decline characterizes the
chronic phase of HIV-2 infection, suggesting that peripheral T-cell homeostasis is controlled better following
HIV-2 infection than following HIV-1 infection. Herein we showed that, in contrast to HIV-1-infected patients,
HIV-2-infected patients demonstrate enhanced thymic function compared to age-matched healthy individuals.
The correlation between higher thymic production and lower CD4 T-cell loss in these patients suggests that
efficient thymopoiesis is implicated in the long-lasting maintenance of CD4 T-cell counts in HIV-2 disease.
Human immunodeficiency virus type 2 (HIV-2) infection is
associated with a more benign course of disease than HIV-1
infection is. The majority of HIV-2-infected individuals remain
asymptomatic for years following infection and their disease
behaves like that of HIV-1-infected long-term nonprogressors,
while the patients who progress to disease exhibit a much
slower rate of CD4 decline than the rate for HIV-1-infected
patients (9, 12, 21). The latter group of HIV-2-infected pa-
tients is reminiscent of HIV-1 slow progressors, characterized
by a slow CD4 T-cell decline despite detectable viremia (3, 13).
Furthermore, studies in geographic areas where high HIV-2
prevalence is observed demonstrated that the life expectancy
for individuals with HIV-2 infection is often close to that of
uninfected individuals living in the same villages (12). The
factors determining the delayed disease progression in HIV-2
infection remain largely unknown (14). Although plasma viral
load is much lower in HIV-2 infection than in HIV-1 infection
(2), the proviral loads of HIV-2-infected patients are similar to
those of HIV-1-infected patients at the same disease stage (10,
11), suggesting that the two viruses do not differ significantly in
their ability to establish infection and replicate in human cells
(1, 17).
On the other hand, similar degrees of T-cell hyperactivation,
as well as increased T-cell cycling, were observed for both
HIV-1- and HIV-2-infected patients with similar degrees of
CD4 depletion (18). This suggests an intimate link between
generalized immune activation and associated cell death and
CD4 depletion in both infections despite distinct viremias and
clinical outcomes.
HIV-1 infection is associated with an impairment of intra-
thymic precursor T-cell proliferation resulting in a huge reduc-
tion of de novo T-cell production thought to participate in the
progressive decline of peripheral CD4 T-cell counts, in partic-
ular in the recent thymic emigrants (RTEs) and naı¨ve T-cell
compartments (4). An imbalance between production and de-
struction of peripheral CD4 T cells would lead to their pro-
gressive decline over time and eventually to AIDS (5, 6).
Moreover, in slow progressor HIV-1-infected patients, we re-
cently demonstrated that the maintenance of circulating CD4
T cells is strongly associated with efficient thymopoiesis (3).
We thus hypothesized that the maintenance of de novo T-
cell production may counteract the peripheral CD4 loss that is
known to occur in HIV-2 infection and represents a major
mechanism underlying the slow progression of HIV-2 disease.
Here we analyzed the role of thymopoiesis in the long-term
maintenance of peripheral CD4 T-cell numbers in a cohort of
untreated chronically HIV-2- and HIV-1-infected subjects cur-
rently living in Portugal and attending outpatient clinics in
Lisbon, Portugal, compared to age-matched healthy individu-
als. A summary of the clinical features of the patients studied
and healthy controls is shown in Table 1.
Thymic activity was estimated by measurement of the intra-
thymic proliferation history of circulating RTEs by quantifica-
tion of the signal joint/beta T-cell receptor excision circle (sj/
TREC) ratio as described previously (3, 4, 20). This marker,
which is independent of peripheral T-cell proliferation and
death rate, directly reflects the number of proliferation cycles
undergone by precursor T cells during their intrathymic differ-
entiation and thus thymic output (4). Surprisingly, while in
both HIV-1 and HIV-2 patients, the younger individuals (35 to
45 years old) demonstrate a low thymic function (median sj/
TREC ratios of 11.3 and 6.5 for HIV-1 and HIV-2 patients,
respectively, compared to a ratio of 24.1 in the healthy control
group [P  0.026 and P  0.02, respectively]; Fig. 1A), a
significantly higher sj/TREC ratio characterizes HIV-2-in-
fected subjects that were 45 years old compared to healthy
controls (median sj/TREC ratio of 17.0 in HIV-2-infected
patients compared to 4.9 in control individuals [P  0.0047];
Fig. 1A). This contrasts with the expected low intrathymic
proliferation observed in age-matched HIV-1-infected patients
(sj/TREC ratio of 6.9). In fact, analysis of the sj/TREC ratio
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as a function of age shows that the expected age dependence of
thymic output is not observed in the HIV-2-infected patients
(Fig. 1B). While most patients with chronic HIV-1 infection
demonstrate a rapid and persistent defect in thymic output (3,
4), the impairment of thymopoiesis observed in the younger
groups of HIV-2-infected patients is not further exacerbated
by aging. In contrast, it seems that this function is maintained
in this group of patients, so that in aged individuals, the sj/
TREC ratio becomes greater than in healthy individuals,
most likely leading to long-term sustained thymic output.
To assess the impact of our observations on the peripheral
RTE subset, we evaluated the frequency of sjTREC-containing
cells (sjTREC/105 cells) in peripheral blood mononuclear cells
from all patients studied. A significant reduction of the
sjTREC-positive cell frequency was shown in HIV-2-infected
patients compared to the control group (median sjTREC/105
cells of 102 and 297, respectively; P  0.001 in HIV-2 and
controls). However, this reduction was mainly observed in
younger (35- to 45-year-old) individuals (median sjTREC/105
cells of 558 and 148, respectively; P  0.007 in HIV-2 and
controls; Fig. 2A). In contrast, despite lower CD4 T-cell counts
(Table 1), older individuals (45 years old) had RTE counts
similar to those of age-matched controls (Fig. 2A), supporting
our previous assumption that the increased thymic output
translates into sustained circulating RTE frequency.
Nevertheless, one must consider that the assessment of
sjTREC frequency may be influenced by variable degrees of
immune activation/proliferation in the groups studied. We thus
also determined the sjTREC concentration (sjTREC/ml of
blood) which, although influenced by thymic output and RTE
survival, does not depend upon the general state of immune
activation/proliferation (7, 8).
Interestingly, the analysis of the sjTREC concentration also
showed that the patients that were 45 years old behave like
age-matched controls do, with a significant reduction charac-
terizing 35- to 45-year-old individuals (median sjTREC/ml of
670 and 1,821 in HIV-2-infected patients and controls, respec-
tively; P  0.02) (Fig. 2B). The parallelism between sjTREC
frequency and concentration (Fig. 2A and B) suggests that the
proliferation of TREC-positive cells is not of major impor-
tance in the regulation of naı¨ve T-cell counts during HIV-2
infection. However, HIV-2- and HIV-1-infected patients with
equivalent degrees of CD4 depletion demonstrate similar en-
hancement of immune activation levels (18, 19). It is thus most
probable, as demonstrated by Sieg et al. in HIV-1 infection
that T cells expressing activation/proliferation markers (CD69,
HLA-DR, Ki-67. . .) in HIV-2 infection are also determined to
TABLE 1. Characteristics of the HIV-1- and HIV-2-infected patients and healthy controls studied
Characteristic
Value for groupa
Controls HIV-1-infected patients HIV-2-infected patients
35 to 45 yr 45 yr 35 to 45 yr 45 yr 35 to 45 yr 45 yr
No. of subjects 11 12 6 9 7 13
Ethnicityb 9 C, 2 A 11 C, 1 A 5 C, 1 A 6 C, 3 A 4 C, 3 A 7 C, 6 A
Age (yr)c 39 (36–45) 54 (46–65) 41 (35–43) 54 (46–65) 38 (35–45) 49 (46–68)
Time (mo) after first
seropositivityc,d
NA NA ND ND 19 (7–133) 18 (2–172)
Viral load (log copies/ml)c NA NA 4.06 (2.63–4.98) 4.55 (3.28–5.41) 200e 200e (200–4,006)
Absolute CD4 count (cells/ml)c 920 (535–1,867) 882 (347–1,758) 291** (92–704) 240** (88–986) 927 (333–1,184) 593* (220–830)
Absolute CD8 count (cells/ml)c 336 (105–1,236) 265 (99–770) 654* (269–2,007) 781** (518–2,210) 845* (611–1,778) 670** (202–2,180)
a The subjects are grouped by disease status (controls and HIV-1- and HIV-2-infected patients) and age. NA, not applicable; ND, not determined. Statistical
differences between the values for HIV-infected patients and age-matched controls (Mann-Whitney test) are indicated as follows: *, P  0.05; **, P  0.01.
b The number of Caucasians (C) and Africans (A) are shown (all the African subjects had been residing in Europe for several years at the sampling time).
c The median value is shown, and the range is shown in parentheses.
d All the HIV-2-infected individuals were identified as seropositive at their first visit. (The HIV-1 patients were sampled for another cross-sectional study.)
e HIV-2 viremia was quantified by a reverse transcriptase PCR-based test; all but one of the HIV-2 infected patients had a viral load below 200 RNA copies/ml (cutoff
value).
FIG. 1. HIV-2-infected patients demonstrate high thymic function.
(A) The sj/TREC ratio, a measure of thymic activity, was calculated
for healthy individuals (controls [Ctrls]) and HIV-1- and HIV-2-in-
fected patients. The three groups were subdivided into groups by age
(35 to 45 years old and45 years old). Gray symbols represent healthy
control individuals of African origin. Statistical differences (P values)
between the different groups are shown above the values (Mann-
Whitney test). NS, not significant. (B) Correlation between the sj/
TREC ratio and age in healthy controls (white and gray symbols,
representing Caucasian and African individuals, respectively, and
HIV-2-infected patients (black symbols). Spearman’s correlation and
associated probability are shown for the control group.
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die rapidly in vivo (15, 16). This is further emphasized by
analyzing the relationships between the sj/TREC ratio (thy-
mic production) and the sjTREC concentration (approximate
RTE counts). As expected, both parameters correlated nicely
in the control group and the HIV-1-infected patients (r 
0.574 and P  0.006 and r  0.653 and P  0.014, respectively
[Fig. 2C, left graph]). In contrast, in HIV-2-infected patients,
thymic production was not associated with RTE concentration
(Fig. 2C, right graph), demonstrating that the sustained thymic
function in older HIV-2-infected patients does not lead to the
expected enlargement of the TREC-rich T-cell population,
likely being concomitantly expanded by increased cell death
and/or accelerated maturation. This is further emphasized by
the absence of correlation between circulating interleukin 7
levels and sjTREC quantification in HIV-2-infected patients
(1).
In order to estimate the impact of the observed enhanced
thymopoiesis on the relative resistance to disease in the HIV-
2-infected patients, we calculated the rate of CD4 count de-
cline in this group of patients over a median period of 2.5 years
preceding the analysis of thymic function. In HIV-2-infected
patients, the sj/TREC ratio tends to correlate with the vari-
ations in CD4 T-cell counts over time (r  0.432 and P  0.09;
Fig. 3A). Such a correlation does not exist in the HIV-1-
infected patients (r  0.06 and not statistically significant).
Interestingly, when classifying the patients according to their
sj/TREC ratio, a significant difference was observed in their
capacity to maintain CD4 T-cell counts over the follow-up
period. While patients demonstrating efficient thymopoiesis
(i.e., sj/TREC ratio of 10) preserve their CD4 T-cell counts
over the follow-up period (median CD4 change of 25 cells/
FIG. 2. Consequences of the increased thymic function on peripheral RTE population. (A) Relationships between the sjTREC frequency and
age in HIV-2-infected patients and healthy control individuals. (B) Relationships between sjTREC concentration and age in HIV-2-infected
patients and healthy control individuals. In both panels A and B, the white symbols and dashed lines represent healthy controls (gray dots represent
healthy controls of African origin), and the black symbols and solid lines represent the HIV-2-infected patients. The P values from the statistical
analysis (Mann-Whitney test) for each age group are shown above the values. NS, not significant. (C) Relationships between the sjTREC
concentration and thymic function in healthy controls (white and gray symbols, representing Caucasian and African individuals, respectively),
HIV-1-infected patients (left graph, black symbols), and HIV-2-infected patients (right graph). When significant, P values from the statistical
analysis are shown (Spearman’s correlation and associated probability).
FIG. 3. Increased thymic output translates into maintenance of
CD4 counts. (A) Relationships between the sj/TREC ratio and CD4
changes over time in HIV-2-infected patients. The correlation coeffi-
cient (Spearman’s test) and associated probability are shown. (B) CD4
changes in HIV-2-infected patients with sj/TREC ratios of 10 and
10. CD4 change values were calculated using the slope of CD4
counts measured over a period of 2.5 years before sampling. Statis-
tical differences between the two groups (P values) are shown above
the ratios (Mann-Whitney test).
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year [range, 43 to 202]; Fig. 3B), patients with low sj/
TREC ratio (10) show a slow but definite decline in circu-
lating CD4 T-cell numbers (median loss of 40 cells/year
[range, 217 to 19; P  0.023]). In contrast, in the HIV-1-
infected group, the extent of intrathymic precursor T-cell pro-
liferation does not correlate with CD4 T-cell decline (median
CD4 changes of 122 and 73 cells/year in patients with
sj/TREC ratios of 10 and 10, respectively; not statistically
significant; data not shown).
Taken together, these data demonstrate that patients with
chronic HIV-2 infections maintain thymic production for pro-
longed periods of time, even after they reach 45 years of age,
when significant thymic involution is observed in healthy indi-
viduals. This effect, reminiscent of what was observed in HIV-
1-infected slow progressors, suggests that increased CD4 T-cell
death can, at least partly, be compensated for by an overpro-
duction of new T cells in HIV-2-induced pathology. The fact
that younger HIV-2-infected patients demonstrate a reduced
thymic function suggests either that HIV-2 infection can lead
to various levels of pathogenesis or that sustained thymic func-
tion in aging patients is a mechanism that develops slowly to
compensate for increased cell death. Patients who cannot
maintain thymic function would exhibit progressively lower
CD4 T-cell counts, eventually leading to AIDS, while others
whose thymus remains functional maintain CD4 counts and
remain asymptomatic for several decades. However, it is pos-
sible that efficient thymopoiesis is both a cause and conse-
quence of limited pathogenicity in HIV-2. It is quite possible
that low viral loads in HIV-2-infected patients, by inducing
limited homeostatic perturbations, leads to maintained thymic
potential and that when lymphopenia occurs, this capacity of
the thymus to produce new T cells allows the maintenance of
CD4 counts and naı¨ve T-cell diversity sufficiently high to limit
progression of the disease.
Interestingly, Poulsen et al. observed that in some West
African villages, older people (55 to 80 years of age) with
HIV-2 infection have the same mortality risk as uninfected
individuals do (12). The capacity of these patients to maintain
de novo T-cell production through efficient thymopoiesis de-
spite aging may participate to their longevity in the presence of
HIV-2 infection. These new data on the role of the thymus in
this natural model of attenuated HIV infection bring new
arguments to the contribution of ongoing thymopoiesis for
HIV pathogenesis and the rate of progression to AIDS and
strengthen the importance of the thymus as a target for im-
mune-based therapies.
(This work was carried out by D. Gautier in partial fulfill-
ment of the requirements for a doctoral degree at the Univer-
site´ Paris 7 Denis Diderot, Paris, France, 2007.)
This work was supported by the Institut Pasteur and Fundac¸a˜o para
a Cieˆncia e Tecnologia (FCT) from Portugal (grant POCI/SAU-
MMO/60333 to A.E.S.). D.G. was the recipient of a Ph.D. ANRS
scholarship, S.B. was the recipient of a SIDACTION postdoctoral
grant, and C.S.C. received a Ph.D. scholarship from FCT.
REFERENCES
1. Albuquerque, A. S., C. S. Cortesao, R. B. Foxall, R. S. Soares, R. M.
Victorino, and A. E. Sousa. 2007. Rate of increase in circulating IL-7 and loss
of IL-7Ralpha expression differ in HIV-1 and HIV-2 infections: two lym-
phopenic diseases with similar hyperimmune activation but distinct out-
comes. J. Immunol. 178:3252–3259.
2. Damond, F., M. Gueudin, S. Pueyo, I. Farfara, D. L. Robertson, D. Des-
camps, G. Chene, S. Matheron, P. Campa, F. Brun-Vezinet, and F. Simon.
2002. Plasma RNA viral load in human immunodeficiency virus type 2
subtype A and subtype B infections. J. Clin. Microbiol. 40:3654–3659.
3. Dion, M. L., R. Bordi, J. Zeidan, R. Asaad, M. R. Boulassel, J. P. Routy,
M. M. Lederman, R. P. Sekaly, and R. Cheynier. 2007. Slow disease pro-
gression and robust therapy-mediated CD4 T-cell recovery are associated
with efficient thymopoiesis during HIV-1 infection. Blood 109:2912–2920.
4. Dion, M. L., J. F. Poulin, R. Bordi, M. Sylvestre, R. Corsini, N. Kettaf, A.
Dalloul, M. R. Boulassel, P. Debre, J. P. Routy, Z. Grossman, R. P. Sekaly,
and R. Cheynier. 2004. HIV infection rapidly induces and maintains a sub-
stantial suppression of thymocyte proliferation. Immunity 21:757–768.
5. Grossman, Z., M. Meier-Schellersheim, W. E. Paul, and L. J. Picker. 2006.
Pathogenesis of HIV infection: what the virus spares is as important as what
it destroys. Nat. Med. 12:289–295.
6. Grossman, Z., M. Meier-Schellersheim, A. E. Sousa, R. M. Victorino, and
W. E. Paul. 2002. CD4 T-cell depletion in HIV infection: are we closer to
understanding the cause? Nat. Med. 8:319–323.
7. Hazenberg, M. D., S. A. Otto, J. W. Cohen Stuart, M. C. Verschuren, J. C.
Borleffs, C. A. Boucher, R. A. Coutinho, J. M. Lange, T. F. Rinke de Wit, A.
Tsegaye, J. J. van Dongen, D. Hamann, R. J. de Boer, and F. Miedema. 2000.
Increased cell division but not thymic dysfunction rapidly affects the T-cell
receptor excision circle content of the naive T-cell population in HIV-1
infection. Nat. Med. 6:1036–1042.
8. Hazenberg, M. D., M. C. Verschuren, D. Hamann, F. Miedema, and J. J. van
Dongen. 2001. T cell receptor excision circles as markers for recent thymic
emigrants: basic aspects, technical approach, and guidelines for interpreta-
tion. J. Mol. Med. 79:631–640.
9. Marlink, R., P. Kanki, I. Thior, K. Travers, G. Eisen, T. Siby, I. Traore, C. C.
Hsieh, M. C. Dia, E. H. Gueye, et al. 1994. Reduced rate of disease devel-
opment after HIV-2 infection as compared to HIV-1. Science 265:1587–
1590.
10. Popper, S. J., A. D. Sarr, A. Gueye-Ndiaye, S. Mboup, M. E. Essex, and P. J.
Kanki. 2000. Low plasma human immunodeficiency virus type 2 viral load is
independent of proviral load: low virus production in vivo. J. Virol. 74:1554–
1557.
11. Popper, S. J., A. D. Sarr, K. U. Travers, A. Gueye-Ndiaye, S. Mboup, M. E.
Essex, and P. J. Kanki. 1999. Lower human immunodeficiency virus (HIV)
type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.
J. Infect. Dis. 180:1116–1121.
12. Poulsen, A. G., P. Aaby, O. Larsen, H. Jensen, A. Naucler, I. M. Lisse, C. B.
Christiansen, F. Dias, and M. Melbye. 1997. 9-Year HIV-2-associated mor-
tality in an urban community in Bissau, West Africa. Lancet 349:911–914.
13. Rodes, B., C. Toro, E. Paxinos, E. Poveda, M. Martinez-Padial, J. M. Benito,
V. Jimenez, T. Wrin, S. Bassani, and V. Soriano. 2004. Differences in disease
progression in a cohort of long-term non-progressors after more than 16
years of HIV-1 infection. AIDS 18:1109–1116.
14. Rowland-Jones, S. L., and H. C. Whittle. 2007. Out of Africa: what can we
learn from HIV-2 about protective immunity to HIV-1? Nat. Immunol.
8:329–331.
15. Sieg, S. F., C. V. Harding, and M. M. Lederman. 2001. HIV-1 infection
impairs cell cycle progression of CD4 T cells without affecting early acti-
vation responses. J. Clin. Investig. 108:757–764.
16. Sieg, S. F., J. B. Mitchem, D. A. Bazdar, and M. M. Lederman. 2002. Close
link between CD4 and CD8 T cell proliferation defects in patients with
human immunodeficiency virus disease and relationship to extended periods
of CD4 lymphopenia. J. Infect. Dis. 185:1401–1416.
17. Soares, R., R. Foxall, A. Albuquerque, C. Cortesao, M. Garcia, R. M. Vic-
torino, and A. E. Sousa. 2006. Increased frequency of circulating CCR5
CD4 T cells in human immunodeficiency virus type 2 infection. J. Virol.
80:12425–12429.
18. Sousa, A. E., J. Carneiro, M. Meier-Schellersheim, Z. Grossman, and R. M.
Victorino. 2002. CD4 T cell depletion is linked directly to immune activation
in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.
J. Immunol. 169:3400–3406.
19. Sousa, A. E., A. F. Chaves, A. Loureiro, and R. M. Victorino. 2001. Com-
parison of the frequency of interleukin (IL)-2-, interferon-gamma-, and
IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1
and 2, with distinct clinical outcomes. J. Infect. Dis. 184:552–559.
20. van den Dool, C., and R. J. de Boer. 2006. The effects of age, thymectomy,
and HIV infection on alpha and beta TCR excision circles in naive T cells.
J. Immunol. 177:4391–4401.
21. Whittle, H., J. Morris, J. Todd, T. Corrah, S. Sabally, J. Bangali, P. T. Ngom,
M. Rolfe, and A. Wilkins. 1994. HIV-2-infected patients survive longer than
HIV-1-infected patients. AIDS 8:1617–1620.
12688 NOTES J. VIROL.
 o
n
 June 6, 2015 by UNIV O
F CALIF SAN DIEG
O
http://jvi.asm.org/
D
ow
nloaded from
 
